Literature DB >> 30032243

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

F Cardoso1, E Senkus2, A Costa3, E Papadopoulos4, M Aapro5, F André6, N Harbeck7, B Aguilar Lopez8, C H Barrios9, J Bergh10, L Biganzoli11, C B Boers-Doets12, M J Cardoso13, L A Carey14, J Cortés15, G Curigliano16, V Diéras17, N S El Saghir18, A Eniu19, L Fallowfield20, P A Francis21, K Gelmon22, S R D Johnston23, B Kaufman24, S Koppikar25, I E Krop26, M Mayer27, G Nakigudde28, B V Offersen29, S Ohno30, O Pagani31, S Paluch-Shimon32, F Penault-Llorca33, A Prat34, H S Rugo35, G W Sledge36, D Spence37, C Thomssen38, D A Vorobiof39, B Xu40, L Norton41, E P Winer42.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30032243      PMCID： PMC7360146          DOI： 10.1093/annonc/mdy192

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  59 in total

1.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.

Authors:  C A Dykewicz
Journal:  Clin Infect Dis       Date:  2001-06-14       Impact factor: 9.079

2.  Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F A Peccatori; H A Azim; R Orecchia; H J Hoekstra; N Pavlidis; V Kesic; G Pentheroudakis
Journal:  Ann Oncol       Date:  2013-06-27       Impact factor: 32.976

3.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017.

Authors:  Cornelia Liedtke; Marc Thill; Christian Jackisch; Christoph Thomssen; Volkmar Müller; Wolfgang Janni; Wolfgang Janni
Journal:  Breast Care (Basel)       Date:  2017-06-21       Impact factor: 2.860

4.  2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Authors:  F Roila; A Molassiotis; J Herrstedt; M Aapro; R J Gralla; E Bruera; R A Clark-Snow; L L Dupuis; L H Einhorn; P Feyer; P J Hesketh; K Jordan; I Olver; B L Rapoport; J Roscoe; C H Ruhlmann; D Walsh; D Warr; M van der Wetering
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

5.  Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Authors:  Tiffany A Traina; Kathy Miller; Denise A Yardley; Janice Eakle; Lee S Schwartzberg; Joyce O'Shaughnessy; William Gradishar; Peter Schmid; Eric Winer; Catherine Kelly; Rita Nanda; Ayca Gucalp; Ahmad Awada; Laura Garcia-Estevez; Maureen E Trudeau; Joyce Steinberg; Hirdesh Uppal; Iulia Cristina Tudor; Amy Peterson; Javier Cortes
Journal:  J Clin Oncol       Date:  2018-01-26       Impact factor: 44.544

Review 6.  Complementary and integrative medicine for breast cancer patients - Evidence based practical recommendations.

Authors:  C M Witt; M J Cardoso
Journal:  Breast       Date:  2016-05-17       Impact factor: 4.380

7.  Palbociclib and Letrozole in Advanced Breast Cancer.

Authors:  Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

8.  Oncofertility: Fertile Ground for Conflict Between Patient Autonomy and Medical Values.

Authors:  Sarah K Walsh; Elizabeth S Ginsburg; Lisa Soleymani Lehmann; Ann H Partridge
Journal:  Oncologist       Date:  2017-04-13

Review 9.  Bevacizumab for the Treatment of Radiation-Induced Cerebral Necrosis: A Systematic Review of the Literature.

Authors:  Durim Delishaj; Stefano Ursino; Francesco Pasqualetti; Agostino Cristaudo; Mirco Cosottini; Maria Grazia Fabrini; Fabiola Paiar
Journal:  J Clin Med Res       Date:  2017-02-21

10.  Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.

Authors:  Sunil Verma; Joyce O'Shaughnessy; Howard A Burris; Mario Campone; Emilio Alba; David Chandiwana; Anand A Dalal; Santosh Sutradhar; Mauricio Monaco; Wolfgang Janni
Journal:  Breast Cancer Res Treat       Date:  2018-04-13       Impact factor: 4.872
View more
  302 in total

1.  Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy.

Authors:  Shogo Nakamoto; Junichiro Watanabe; Shoichiro Ohtani; Satoshi Morita; Masahiko Ikeda
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Resection of liver metastases from breast cancer: a multicentre analysis.

Authors:  X He; Q Zhang; Y Feng; Z Li; Q Pan; Y Zhao; W Zhu; N Zhang; J Zhou; L Wang; M Wang; Z Liu; H Zhu; Z Shao; L Wang
Journal:  Clin Transl Oncol       Date:  2019-06-22       Impact factor: 3.405

3.  PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.

Authors:  Lidija Antunovic; Rita De Sanctis; Luca Cozzi; Margarita Kirienko; Andrea Sagona; Rosalba Torrisi; Corrado Tinterri; Armando Santoro; Arturo Chiti; Renata Zelic; Martina Sollini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-26       Impact factor: 9.236

4.  Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.

Authors:  Mark Robson; Kathryn J Ruddy; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Wei Li; Nadine Tung; Anne Armstrong; Suzette Delaloge; Wendy Bannister; Carsten Goessl; Arnold Degboe; Robert Hettle; Pierfranco Conte
Journal:  Eur J Cancer       Date:  2019-08-22       Impact factor: 9.162

Review 5.  Breast cancer: an update on treatment-related infertility.

Authors:  Erica Silvestris; Miriam Dellino; Paola Cafforio; Angelo Virgilio Paradiso; Gennaro Cormio; Stella D'Oronzo
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-31       Impact factor: 4.553

Review 6.  Health system strengthening: Integration of breast cancer care for improved outcomes.

Authors:  Susan Horton; Rolando Camacho Rodriguez; Benjamin O Anderson; Soe Aung; Baffour Awuah; Lucia Delgado Pebé; Catherine Duggan; Allison Dvaladze; Somesh Kumar; Raúl Murillo; Rai Mra; Anne F Rositch; Mutumba Songiso; Richard Sullivan; Audrey T Tsunoda; Soo-Hwang Teo; Hellen Gelband
Journal:  Cancer       Date:  2020-05-15       Impact factor: 6.860

7.  The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource-Stratified Phased Implementation: Methods and overview.

Authors:  Catherine Duggan; Allison Dvaladze; Anne F Rositch; Ophira Ginsburg; Cheng-Har Yip; Susan Horton; Rolando Camacho Rodriguez; Alexandru Eniu; Miriam Mutebi; Jean-Marc Bourque; Shahla Masood; Karla Unger-Saldaña; Anna Cabanes; Robert W Carlson; Julie R Gralow; Benjamin O Anderson
Journal:  Cancer       Date:  2020-05-15       Impact factor: 6.860

8.  The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer.

Authors:  Jan Haussmann; Christiane Matuschek; Edwin Bölke; Klaus Orth; Pirus Ghadjar; Wilfried Budach
Journal:  Dtsch Arztebl Int       Date:  2019-12-13       Impact factor: 5.594

9.  Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.

Authors:  Francesco Schettini; Fabiola Giudici; Mario Giuliano; Massimo Cristofanilli; Grazia Arpino; Lucia Del Mastro; Fabio Puglisi; Sabino De Placido; Ida Paris; Pietro De Placido; Sergio Venturini; Michelino De Laurentis; PierFranco Conte; Dejan Juric; Antonio Llombart-Cussac; Lajos Pusztai; Aleix Prat; Guy Jerusalem; Angelo Di Leo; Daniele Generali
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

Review 10.  Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.

Authors:  Connie Kang; Yahiya Y Syed
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.